Related Experiment Videos
Treating patients with acute gastrointestinal bleeding or rebleeding
1Division of Gastroenterology and Hepatology, Veteran Affairs Greater Los Angeles Healthcare System at West Los Angeles, 11301 Wilshire Boulevard, CA 90073, USA. jpisegna@ucla.edu
Pharmacotherapy
|November 1, 2003
Summary
Gastrointestinal bleeding poses significant health risks. Intravenous proton pump inhibitors (PPIs) offer an effective treatment option for hospitalized patients, unlike less effective histamine2-receptor antagonists (H2RAs).
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Gastrointestinal bleeding (GIB) is a major cause of morbidity and mortality, with high-risk groups including those with prior GIB, NSAID use, or peptic ulcer disease.
- Current management involves endoscopy and antisecretory therapy to control gastric acid, treat ulcers, and alleviate symptoms.
Observation:
- Histamine2-receptor antagonists (H2RAs) often fail to achieve target gastric pH in GIB due to tachyphylaxis.
- Proton pump inhibitors (PPIs) are more effective in acid suppression and do not exhibit tachyphylaxis.
Findings:
- Intravenous pantoprazole, a proton pump inhibitor (PPI), expands treatment options for hospitalized patients experiencing gastrointestinal bleeding.
- PPIs demonstrate superior efficacy over H2RAs in maintaining gastric pH for GIB management.
Implications:
- The availability of intravenous PPIs improves therapeutic strategies for severe gastrointestinal bleeding.
- Enhanced acid control with PPIs may lead to better outcomes in high-risk GIB patients.